Low Dose Cyclosporin-A Therapy in Behcet's Disease

Abstract

The effect of systemic low dose cyclosporin-A (5 mg/kg/day as initial dose) combined with 0.2 to 0.6 mg/kg/day prednisolone (when necessary) in clinical course of 22 patients suffering from severe forms of Behcet's disease are reviewed. All the patients had received other drugs previously and had either no response to them or developed intolerable side effects, therefore, pre treatment visual acuity (VA) was compared to post treatment VA as "self control". The average age of our patients was 30.6 years (range 19-51 years). The average duration of our therapy was 19.5 months (range 4-32 months). Improvement or stabilization of vision was achieved in 21 patients (95%). The intraocular inflammation was controlled in all of the eyes and most of the non-ocular signs and symptoms were also improved. Serious side effects included rise in creatinine in 10 (45%) of the patients, rise in bilirubin in 6 (27%) and hypertension in 1 (4.5%). These side effects disappeared as the dose of cyclosporin-A was tapered. We believe this form of therapy is of great value in the management of severe forms of Behcet's disease.

Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease

“…Among the 15 open studies with ciclosporin A in eye disease, all supporting its efficacy, 13 also provided data on safety (table 3). 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Ciclosporin dose was between 2–10 mg/kg/day and the mean (SD) duration of treatment was 19.1 (16.2) months in these studies.…”

Update on the therapy of Behçet disease

“…Azathioprine Eye involvement RCT [Yazici et al 1990] Retrospective study [Saadoun et al 2010] Vascular disease RCT [Yazici et al 1990] GI involvement Retrospective study Neuro-Behçet Case series [Kurtuncu et al 2008] Mycophenolate mofetil Neuro-Behçet Case series [Shugaiv et al 2011] Cyclosporine A Eye involvement RCTs [Ozyazgan et al 1992;Masuda et al 1989;BenEzra et al 1988] Open-label studies [Ermakova, 2003;Ozdal et al 2002;Fujino et al 1999;Sullu et al 1998;Whitcup et al 1994;Sajjadi et al 1994;Pacor et al 1994;Hayasaka et al 1994;Atmaca and Batioglu, 1994;Chavis et al 1992; [Mochizuki et al 1991[Mochizuki et al , 1992Ishioka et al 1994] Cyclophosphamide Vascular disease Retrospective studies [Hamuryudan et al 1994[Hamuryudan et al , 2004 Neuro-Behçet Retrospective study...…”

Management of Sarcoidosis, Behçet's Disease, and Other Rare Rheumatic Diseases

“…High dose glucocorticoid therapy helps reduce the acute inflammatory features of severe disease, but additional immunosuppressive agents are usually necessary to prevent disease relapse while tapering. 92 Venous thrombosis is treated with standard anticoagulation regimens. 88 Infliximab, cyclophosphamide, cyclosporine, and azathioprine have all been employed in the treatment of serious complications of BD, but evidence-based data on efficacy are limited.…”